|
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion- adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age |
Waddington CS, Andrews N, Hoschler K, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Waddington CS, Andrews N, Hoschler K, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion- adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technology Assessment 2010; 14(46): 1-130 Authors' conclusions In this first direct comparison of an AS03B-adjuvanted split-virion vaccine versus whole-virion non-adjuvanted H1N1 vaccine, the adjuvanted vaccine – while reactogenic – was more immunogenic, especially in younger children, indicating the potential for improved immunogenicity of influenza vaccines in this age group. INAHTA brief and checklist Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Viral /biosynthesis /blood; Child; Child, Preschool; Disease Outbreaks /statistics & Drug Combinations; Emulsions; Female; Great Britains; Immunization Programs; Infant; Influenza A Virus, H1N1 Subtype /immunology; Influenza Vaccines /administration & Influenza, Human /prevention & Male; Polysorbates /administration & Program Evaluation; Squalene /administration & alpha-Tocopherol /administration & control; dosage; dosage /adverse effects /immunology /standards; dosage /immunology; dosage /immunology; numerical data Language Published English Country of organisation England Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010001172 Date abstract record published 20/10/2010 |
|
|
|